AKT1 and cancer: PARP-1 antagonizes the activity of the PI3K/Akt pathway; the PI3K/Akt pathway enhances glycolytic flux through glucose transposters (GLUTs), HK, and PFK2, and promotes nucleotide, protein, and lipid biosynthesis and autophagy in cancer [76,197].